WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII - News), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it will webcast its Second Annual Investor Event being held Monday, October 5, 2009 at 8:30 a.m. ET in New York City. The event will feature presentations by the Company's senior management team including:
| Tod Woolf, Ph.D., President and Chief Executive Officer |
| Craig Mello, Ph.D., Founder and Chairman of RXi's Scientific Advisory Board |
| Anastasia Khvorova, Ph.D., Chief Scientific Officer |
| Ramani Varanasi, MS, MBA, Vice President, Business Development |
A live webcast of the Investor Event will be available on the "Investors Relations" section of the company's website at www.rxipharma.com. A replay will be available for 30 days.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi has a comprehensive therapeutic platform that includes both RNAi compounds and delivery technologies. RXi uses its own version of RNAi compounds -- rxRNA™ -- that provide an advanced alternative to conventional small interfering RNAs (siRNAs) and define the next generation of RNAi technology. rxRNA™ compounds are designed specifically for therapeutic use and contain many of the properties needed to rapidly advance RNAi based drugs into the clinic. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is experienced in developing RNAi products; and a strong early intellectual property position in RNAi chemistry and delivery.www.rxipharma.com
No comments:
Post a Comment